Wilmer Cutler Pickering Hale and Dorr represented CH Investment Partners in the transaction. Cresset Asset Management (“Cresset”) , an independent investment firm, announced its acquisition of...
Cresset’s Acquisition of CH Investment Partners
CorroHealth’s $365 Million Acquisition of Navient’s Healthcare Services Business
Wilmer Cutler Pickering Hale and Dorr represented Navient Corporation in the offering. Navient Corporation (Nasdaq: NAVI), a provider of technology-enabled education finance and business processing solutions,...
Spectris’ Acquisition of Micromeritics
Wilmer Cutler Pickering Hale and Dorr represented Spectris in the transaction. Spectris plc (SXS: LSE), the expert in providing insight through precision measurement, announced that it...
Agios Pharmaceutical’s $905 Million Purchase Agreement for Vorasidenib Royalty
Wilmer Cutler Pickering Hale and Dorr represented Agios Pharmaceuticals, Inc. in the deal. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation...
Apellis Pharmaceuticals’ $475 Million Financing Agreement with Sixth Street
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals, Inc. on the deal, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Eose advised Sixth...
Karyopharm’s Refinancing Transactions and Amended Royalty Agreement
Wilmer Cutler Pickering Hale and Dorr advised Karyopharm Therapeutics Inc. on the transactions. Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
MicroStrategy’s $800 Million Convertible Senior Notes Offering
Wilmer Cutler Pickering Hale and Dorr represented MicroStrategy® Incorporated in the offering, and Davis Polk & Wardwell advised the representative of the initial purchasers. MicroStrategy Incorporated...
Royalty Pharma’s $1.5 Billion Acquisition of PTC Therapeutics’ Royalties
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
Wonder Group’s $103 Million Acquisition of Blue Apron
Fenwick & West represented Wonder Group in the transaction, and Wilmer Cutler Pickering Hale and Dorr represented Blue Apron Holdings. Wonder Group (“Wonder”) announced that it has...
Blue Apron’s Transaction with FreshRealm
WilmerHale represented Blue Apron in the transaction. Blue Apron (NYSE: APRN), an American ingredient-and-recipe meal kit company, announced the signing and closing of a transaction with...
Houghton Mifflin Harcourt’s $2.8 Billion Merger Agreement with Veritas Capital
Wilmer Cutler Pickering Hale and Dorr advised Houghton Mifflin Harcourt on the deal while Milbank represented Veritas Capital. Houghton Mifflin Harcourt Company (HMH), a learning technology...
PerkinElmer’s $5.25 Billion Acquisition of BioLegend
Wilmer Cutler Pickering Hale and Dorr advised PerkinElmer on the deal while Pillsbury Winthrop Shaw Pittman represented BioLegend. PerkinElmer, a global leader committed to innovating for...